Login to Your Account

Clinic Roundup

Thursday, December 13, 2012

• Hepatera Ltd., of Moscow, a biotech company that is part of Maxwell Biotech Venture Fund's portfolio, said it enrolled the first three patients with chronic hepatitis B virus (HBV) in its Phase Ib/IIa study of Myrcludex B, a drug designed to inhibit the essential HBV receptor on the liver cell surface, preventing the infection of healthy cells and viral spreading in the liver. Results are expected by the end of 2013.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription